Encision Completes $80,000 Private Placement

(PR-inside.com) BOULDER, CO / ACCESS Newswire / September 11, 2026 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced that on September 8, 2026 it completed an $80,000 private placement of common stock with a group of private investors. "We are pleased to have secured necessary funds for general working capital purposes," said Robert Fries, Interim President and CEO of Encision. Pursuant to the securities purchase agreement, the Company issued 2 million common shares at a per share price of $0.04 per common ..

Milan to Host PUBLICHEALTH-2027 on April 19–20, Convening Global Health Stakeholders

PUBLICHEALTH-2027, the 2nd International Conference on Public Health and Health Care System, will take place April 19–20, 2027, in Milan, Italy, gathering global health stakeholders to address emerging public health priorities.

Medical Packaging Films Market: Materials, Applications & Regional Insights

Healthcare packaging is quietly becoming one of the most demanding corners of the materials industry. As drug and device makers push toward smaller, more sensitive, [read full press release...]

McCracken Chiropractic Welcomes New Patients in Calhoun, GA, Offering Drug-Free, Non-Surgical Care for Back Pain, Neck Pain, Sciatica, and Auto Accident Injuries

Optical Outlet Direct Highlights Branded Sunglasses, Professional Eye Care and Australia-Wide Online Shopping from Sydney

Optical Outlet Direct, an independent optical business in Rockdale, Sydney, is highlighting its combination of professional eye care and online access to branded sunglasses.

CTX and P1NP Are the Bone Health Markers That Actually Show What's Happening Right Now

The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome

The U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome Endogenous Cushing's Syndrome is a rare endocrine disorder driven in most cases by excess...

Early Bird Registration Extended for the 23rd Annual Sleep Education Consortium (SEC) Conference “From the Womb to the Tomb”

Medical and Dental professionals can register for the 2027 SEC Sleep Conference at the reduced rate. [PR.com]

Future Horizons Releases "164 Lifehacks for the Highly Sensitive": Your Guide to a Simpler Life by Severine Van De Voorde.

Severine Van De Voorde, PsyD is a clinical psychologist, burnout coach, and expert in high sensitivity and ADHD. She has spent over 10 years studying neuropsychology, and her research has appeared in leading scientific journals. [PR.com]

Clear Health Media Launches Four New iOS Clinical Assessment Apps and Updates Visual Vertical

Melbourne, Australia--(Newsfile Corp. - September 11, 2026) - Clear Health Media, an Australian developer of clinical software, today announced the release of four new iOS applications for clinical assessment, alongside a major update to its established Visual Vertical app."Many established clinical tests remain useful but are still administered using paper, stopwatches or specialised equipment," said Matthew Holmes of Clear Health Media. "Our aim is to use the capabilities already built into an...

Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470

1 La date PDUFA correspond à la date cible à laquelle la Food and Drug Administration (FDA) américaine prévoit d’achever la revue d’une demande d’autorisation de mise sur le marché (NDA) et de rendre sa décision, conformément au Prescription Durg User Fee Act (PDUFA).

Nicox Announces NCX 470 NDA in China Accepted for Review

1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).